|
業務類別
|
Biotechnology |
|
業務概覽
|
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease. |
| 公司地址
| 399 Binney Street, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 857 357-2024 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.citytx.com |
| 員工數量
| 81 |
| Mr. Keith Regnante |
Chief Financial Officer |
-- |
24/09/2026 |
| Mr. Tracy Zimmermann |
Chief Scientific Officer |
-- |
24/09/2026 |
| Mr. Andrew C. Orth |
President, Chief Executive Officer and Director |
-- |
24/09/2026 |
| Dr. Baisong Mei, M.D. |
Chief Medical Officer |
-- |
24/09/2026 |
| Dr. Sebastian Trousil, PhD |
Chief Operating Officer |
-- |
24/09/2026 |
|
|
| Mr. Barry E. Greene |
Director |
24/09/2026 |
| Dr. John M. Maraganore,PhD |
Executive Chairman of the Board |
24/09/2026 |
| Mr. Robert Taylor Nelsen |
Director |
24/09/2026 |
| Dr. Saraswathy V. Nochur, PhD |
Director |
24/09/2026 |
| Mr. Andrew C. Orth |
President, Chief Executive Officer and Director |
24/09/2026 |
| Mr. Ron Philip |
Director |
24/09/2026 |
|
|
|
|